No abstract

The efficacy of emamectin benzoate (SLICE) against sea lice infestations of Atlantic salmon, Salmo salar L., is typically assessed using untreated fish, or fish treated with alternative therapeutants, as controls. The State of Maine, USA, is currently under active management for the OIE-notifiable pathogen, infectious salmon anaemia virus (ISAV); consequently, neither control group is feasible in this region. Untreated salmon risk extensive damage from the ectoparasites, and threaten to increase vector-borne exposure or susceptibility of farms to ISAV; and the only treatment presently available in Maine is SLICE. However, because sea lice infestations are unlikely to resolve spontaneously, and response to treatment occurs within weeks, use of a pretreatment baseline is a reasonable alternative for confirmatory studies. We evaluated SLICE efficacy on Atlantic salmon farms in Cobscook Bay 2002-2005, in the absence of untreated controls, using pretreatment lice loads as a reference for calculation. Maximum efficacy ranged from 68% to 100% reduction from initial levels. Time-to-maximum efficacy ranged from 1 to 8 weeks after treatment initiation. Efficacy duration, measured between first reduction and first progressive rise in counts, ranged from 4 to 16 weeks.

The distribution of infectious salmon anaemia (ISA) was examined among 80 cages from three Atlantic salmon grow-out farms in Maine, USA that were stocked with smolts from a single hatchery. Cage-level disease was broadly defined as one or more moribund fish testing positive for infectious salmon anaemia virus (ISAV) by RT-PCR and a second confirmatory test (IFAT, culture or genotype sequence). Spatio-temporal and cage-level risks were explored using logistic regression and survival analysis. Non-spatial risk factors associated with ISA, or shortened survival time to disease, included increased predation, trucking company choice for smolt transfers, a finely-sedimented benthic substrate, and smaller average size of smolts at stocking. Univariable analysis identified the time-dependent spatial factor 'adjacency to newly infected cages' to be predictive of new infection in neighbouring cages 11-12 weeks later. However, none of the spatial factors, or their lags retained relevance in multiple-variable models. The results suggest a diffuse distribution of virus exposure throughout infected sites, with host-susceptibility factors probably influencing disease manifestation in individual cages. The narrow focus of the current study may limit application of the findings to other sites and year-classes. However, these data support the relevance of husbandry efforts to optimize fish health in regions affected by ISAV.

Infectious salmon anaemia virus (ISAV) is a pathogen of consequence to farmed Atlantic salmon, Salmo salar L. ISA control centres on active surveillance for early detection by reverse transcription polymerase chain reaction (RT-PCR), indirect fluorescent antibody assay (IFAT) and virus isolation. Because diagnostic test performance varies among populations and laboratories, the Office International des Epizooties (OIE) recommends an evaluation of test accuracy in each region of use. This is complicated in Maine, USA by the co-existence of ISAV genotypes homologous to North American (NA) and European (EU) isolates. While NA ISAV genotypes isolated in Maine are characterized by high morbidity and mortality, the single EU genotype in Maine has not yet been linked to disease or isolated by cell culture. Consequently, distinguishing among genotypes is critical to infection response. Accuracy in NA genotype detection was estimated from ISA surveillance data using latent class models. Results suggested that RT-PCR is an excellent screening test for NA ISAV genotypes in Maine, although probably with reduced specificity in the presence of EU genotypes. IFAT, in contrast, was a poor screening test for detection of ISAV in Maine, although it may be useful in confirmation of NA genotypes during disease outbreaks.

No abstract